Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2015

View Archived Issues

Humanized antibodies against pertussis toxin enhance bacterial clearance in baboon model

Accurin nanoformulations improve antitumor activity and PK/PD profile

Cerulean's tunable nanoparticle-drug conjugates are safe and effective antitumor agents

Phase I safety study of bioactive lipid DS-102 completed

Variant licenses worldwide rights to VAR-200 from L&F Research

Janssen starts first-in-human trial of JNJ-64041809 for prostate cancer

Baxalta releases results from pediatric phase III trial of Adynovate

MAPKK inhibitor shows potential for the treatment of cancer cachexia

Pristiq fails to demonstrate superiority over placebo in pediatric patients with MDD

Stemchymal given FDA orphan drug designation for polyglutamine spinocerebellar ataxia

Dicerna advances program for DCR-PH1 in primary hyperoxaluria type 1

Cell therapy improves functional and structural outcome after muscle trauma

MEDI-3039: a potential therapeutic for TNBC

AntibioTx advances preclinical development of dermal formulation of ATx-201

Stemline Therapeutics opens SL-801 IND

Intratumoral injection of EFEMP1-derived tumor suppression protein shows promise for brain cancer

Merck KGaA and Pfizer advance avelumab with two additional phase III trials

ExCellThera cleared to begin phase I/II trial of ECT-100 for expansion of hematopoietic stem cells

Roche makes available new cobas HBV assay for hepatitis B

Biocartis launches assays for BRAF and Ras pathway mutations

Ketogen patents anticonvulsants

EMA accepts Vanda's MAA for Fanaptum

FDA approves AstraZeneca's Zurampic for hyperuricemia in gout

CSL Behring submits MAA for rFVIII-SingleChain to treat hemophilia A

Sanofi files NDA for LixiLan for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...